603998 方盛制药
交易中 04-30 10:27:17
资讯
新帖
简况
方盛制药(603998)2026年一季报简析:营收净利润同比双双增长
证券之星 · 04-26
方盛制药(603998)2026年一季报简析:营收净利润同比双双增长
图解方盛制药年报:第四季度单季净利润同比增长40.72%
证券之星 · 04-25
图解方盛制药年报:第四季度单季净利润同比增长40.72%
每周股票复盘:方盛制药(603998)将召开2025年年度暨2026年一季度业绩说明会
证券之星 · 04-19
每周股票复盘:方盛制药(603998)将召开2025年年度暨2026年一季度业绩说明会
方盛制药(603998)披露2025年年度暨2026年一季度业绩说明会安排,4月17日股价下跌3.63%
证券之星 · 04-17
方盛制药(603998)披露2025年年度暨2026年一季度业绩说明会安排,4月17日股价下跌3.63%
每周股票复盘:方盛制药(603998)《药品生产许可证》变更
证券之星 · 04-12
每周股票复盘:方盛制药(603998)《药品生产许可证》变更
方盛制药(603998)披露公司《药品生产许可证》变更公告,4月7日股价上涨0.65%
证券之星 · 04-07
方盛制药(603998)披露公司《药品生产许可证》变更公告,4月7日股价上涨0.65%
每周股票复盘:方盛制药(603998)司来帕格片获注册证书
证券之星 · 03-29
每周股票复盘:方盛制药(603998)司来帕格片获注册证书
股市必读:方盛制药(603998)3月23日收盘跌7.32%,主力净流入1398.25万元
证券之星 · 03-24
股市必读:方盛制药(603998)3月23日收盘跌7.32%,主力净流入1398.25万元
方盛制药最新公告:司来帕格片获药品注册证书
证券之星 · 03-23
方盛制药最新公告:司来帕格片获药品注册证书
每周股票复盘:方盛制药(603998)多款产品中选集采
证券之星 · 03-08
每周股票复盘:方盛制药(603998)多款产品中选集采
方盛制药(603998)披露比索洛尔氨氯地平片获得《药品注册证书》公告,3月5日股价上涨0.6%
证券之星 · 03-05
方盛制药(603998)披露比索洛尔氨氯地平片获得《药品注册证书》公告,3月5日股价上涨0.6%
方盛制药(603998.SH):比索洛尔氨氯地平片获得药品注册证书
智通财经 · 03-04
方盛制药(603998.SH):比索洛尔氨氯地平片获得药品注册证书
方盛制药(603998.SH)部分产品中选集采药品协议期满品种接续采购
智通财经 · 03-02
方盛制药(603998.SH)部分产品中选集采药品协议期满品种接续采购
每周股票复盘:方盛制药(603998)张庆华解除质押962.52万股
证券之星 · 03-01
每周股票复盘:方盛制药(603998)张庆华解除质押962.52万股
方盛制药(603998)披露控股股东部分股份解除质押公告,2月25日股价下跌0.48%
证券之星 · 02-25
方盛制药(603998)披露控股股东部分股份解除质押公告,2月25日股价下跌0.48%
股市必读:方盛制药(603998)2月13日披露最新机构调研信息
证券之星 · 02-24
股市必读:方盛制药(603998)2月13日披露最新机构调研信息
【机构调研记录】平安基金调研泽璟制药、方盛制药
证券之星 · 02-16
【机构调研记录】平安基金调研泽璟制药、方盛制药
股市必读:方盛制药(603998)2月11日披露最新机构调研信息
证券之星 · 02-12
股市必读:方盛制药(603998)2月11日披露最新机构调研信息
方盛制药:公司董事会、管理层高度重视市值维护
证券日报 · 02-10
方盛制药:公司董事会、管理层高度重视市值维护
方盛制药(603998.SH)控股子公司获得《药品生产许可证》
智通财经 · 02-05
方盛制药(603998.SH)控股子公司获得《药品生产许可证》
加载更多
公司概况
公司名称:
湖南方盛制药股份有限公司
所属行业:
医药制造业
上市日期:
2014-12-05
主营业务:
湖南方盛制药股份有限公司的主营业务是药品的研发、生产与销售。公司的主要产品是血塞通分散片、血塞通片、藤黄健骨片、赖氨酸维B12颗粒、头孢克肟片、金英胶囊、蒲地蓝消炎片、小儿荆杏止咳颗粒、依折麦布片、玄七健骨片、强力枇杷膏(蜜炼)、强力枇杷露。近三年(2023-2025年)公司先后获得国家绿色工厂、中成药百强工业、湖南省智能制造标杆车间、湖南省消费品工业“三品”标杆企业、湖南省“高新技术企业税收贡献百强”等多项荣誉称号。
发行价格:
14.85
{"stockData":{"symbol":"603998","market":"SH","secType":"STK","nameCN":"方盛制药","latestPrice":11.09,"timestamp":1777516037000,"preClose":10.98,"halted":0,"volume":4661600,"delay":0,"changeRate":0.01,"floatShares":438999999,"shares":438999999,"eps":0.6981,"marketStatus":"交易中","change":0.11,"latestTime":"04-30 10:27:17","open":10.96,"high":11.11,"low":10.96,"amount":51527500,"amplitude":0.0137,"askPrice":11.09,"askSize":109,"bidPrice":11.08,"bidSize":1105,"shortable":0,"etf":0,"ttmEps":0.6981,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1777519800000},"marketStatusCode":2,"adr":0,"adjPreClose":10.98,"symbolType":"stock","openAndCloseTimeList":[[1777512600000,1777519800000],[1777525200000,1777532400000]],"highLimit":12.08,"lowLimit":9.88,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":439081360,"isCdr":false,"pbRate":2.78,"roa":"--","peRate":15.885976,"roe":"5.16%","epsLYR":0.7,"committee":-0.222899,"marketValue":4869000000,"turnoverRate":0.0106,"status":0,"floatMarketCap":4869000000},"requestUrl":"/m/hq/s/603998","defaultTab":"news","newsList":[{"id":"2630380710","title":"方盛制药(603998)2026年一季报简析:营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2630380710","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630380710?lang=zh_cn&edition=full","pubTime":"2026-04-26 06:15","pubTimestamp":1777155335,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期方盛制药发布2026年一季报。根据财报显示,方盛制药营收净利润同比双双增长。截至本报告期末,公司营业总收入4.63亿元,同比上升10.69%,归母净利润8839.17万元,同比上升0.15%。持有方盛制药最多的基金为融通健康产业灵活配置混合A/B,目前规模为14.07亿元,最新净值2.664,较上一交易日上涨0.11%,近一年上涨13.03%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600003107.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630290408","title":"图解方盛制药年报:第四季度单季净利润同比增长40.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630290408","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630290408?lang=zh_cn&edition=full","pubTime":"2026-04-25 01:32","pubTimestamp":1777051922,"startTime":"0","endTime":"0","summary":"证券之星消息,方盛制药2025年年报显示,当年度公司主营收入17.46亿元,同比下降1.75%;归母净利润3.06亿元,同比上升20.05%;扣非净利润2.48亿元,同比上升28.69%;其中2025年第四季度,公司单季度主营收入4.93亿元,同比上升14.81%;单季度归母净利润3810.38万元,同比上升40.72%;单季度扣非净利润3581.47万元,同比上升18.71%;负债率41.0%,投资收益168.87万元,财务费用1112.84万元,毛利率71.97%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500004367.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628564367","title":"每周股票复盘:方盛制药(603998)将召开2025年年度暨2026年一季度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2628564367","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628564367?lang=zh_cn&edition=full","pubTime":"2026-04-19 01:46","pubTimestamp":1776534370,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘,方盛制药报收于10.35元,较上周的10.82元下跌4.34%。本周,方盛制药4月15日盘中最高价报10.95元。方盛制药当前最新总市值45.44亿元,在中药板块市值排名44/66,在两市A股市值排名3702/5198。本周关注点公司公告汇总:方盛制药将于2026年4月27日召开2025年年度暨2026年第一季度业绩说明会。投资者可于2026年4月20日至4月24日16:00前通过上证路演中心网站或公司邮箱提交问题,公司将在说明会上对普遍关注的问题进行回应。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900000552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","603998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628911202","title":"方盛制药(603998)披露2025年年度暨2026年一季度业绩说明会安排,4月17日股价下跌3.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628911202","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628911202?lang=zh_cn&edition=full","pubTime":"2026-04-17 22:08","pubTimestamp":1776434902,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘,方盛制药报收于10.35元,较前一交易日下跌3.63%,最新总市值为45.44亿元。近日,方盛制药发布《关于召开2025年年度暨2026年一季度业绩说明会的公告》。公告显示,公司将于2026年4月27日09:00-10:00通过上证路演中心网络互动方式召开业绩说明会,介绍公司经营成果和财务状况。投资者可于2026年4月20日至4月24日16:00前通过上证路演中心网站或公司邮箱提交问题,公司将在说明会上对普遍关注的问题进行回应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700045520.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","603998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626122399","title":"每周股票复盘:方盛制药(603998)《药品生产许可证》变更","url":"https://stock-news.laohu8.com/highlight/detail?id=2626122399","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626122399?lang=zh_cn&edition=full","pubTime":"2026-04-12 01:40","pubTimestamp":1775929216,"startTime":"0","endTime":"0","summary":"截至2026年4月10日收盘,方盛制药报收于10.82元,较上周的10.85元下跌0.28%。本周,方盛制药4月8日盘中最高价报11.15元。本周关注点公司公告汇总:方盛制药《药品生产许可证》变更,涉及质量负责人及生产范围调整。公司公告汇总方盛制药关于公司《药品生产许可证》变更的公告湖南方盛制药股份有限公司近日完成《药品生产许可证》变更,取得湖南省药品监督管理局核发的新证。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200000355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","603998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625198959","title":"方盛制药(603998)披露公司《药品生产许可证》变更公告,4月7日股价上涨0.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625198959","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625198959?lang=zh_cn&edition=full","pubTime":"2026-04-07 22:23","pubTimestamp":1775571798,"startTime":"0","endTime":"0","summary":"截至2026年4月7日收盘,方盛制药报收于10.92元,较前一交易日上涨0.65%,最新总市值为47.95亿元。该股当日开盘10.85元,最高11.1元,最低10.76元,成交额达8634.85万元,换手率为1.8%。近日,湖南方盛制药股份有限公司完成《药品生产许可证》变更,取得湖南省药品监督管理局核发的新证。本次变更不影响公司现有生产结构,不构成重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700033538.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","603998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623338710","title":"每周股票复盘:方盛制药(603998)司来帕格片获注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2623338710","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623338710?lang=zh_cn&edition=full","pubTime":"2026-03-29 03:50","pubTimestamp":1774727420,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘,方盛制药报收于11.09元,较上周的11.2元下跌0.98%。本周关注点公司公告汇总:司来帕格片获《药品注册证书》,为公司首个血液和造血系统药物。截至公告披露日,佰骏医疗已累计偿还11,200万元,尚余5,332.79万元未还。方盛制药关于司来帕格片获得《药品注册证书》的公告2026年3月20日,湖南方盛制药股份有限公司收到国家药品监督管理局核准签发的《药品注册证书》,公司研发的司来帕格片获得药品批准文号,可进行生产。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900000883.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603998","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621085165","title":"股市必读:方盛制药(603998)3月23日收盘跌7.32%,主力净流入1398.25万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621085165","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621085165?lang=zh_cn&edition=full","pubTime":"2026-03-24 02:06","pubTimestamp":1774289174,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘,方盛制药报收于10.38元,下跌7.32%,换手率3.41%,成交量14.99万手,成交额1.59亿元。当日关注点来自交易信息汇总:方盛制药股价连续3日下跌,累计跌幅达12.79%,主力资金前10日净流出超5000万元。交易信息汇总3月23日方盛制药收盘报10.38元,跌7.32%,当日成交1499.22万元。受春节假期等因素影响,佰骏医疗未能按期足额还款,已于2026年3月20日偿还300万元,剩余300万元预计于4月底前偿还。截至公告日,研发投入累计1,678.92万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400001922.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","603998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621749047","title":"方盛制药最新公告:司来帕格片获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2621749047","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621749047?lang=zh_cn&edition=full","pubTime":"2026-03-23 17:56","pubTimestamp":1774259807,"startTime":"0","endTime":"0","summary":"方盛制药(603998.SH)公告称,公司近日收到国家药监局核准签发的《药品注册证书》,公司研发的司来帕格片已获得药品批准文号,并可进行生产。该药品为化学药品4类,系公司首个血液和造血系统药物。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300028397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603998","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617663548","title":"每周股票复盘:方盛制药(603998)多款产品中选集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2617663548","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617663548?lang=zh_cn&edition=full","pubTime":"2026-03-08 03:10","pubTimestamp":1772910624,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘,方盛制药报收于12.11元,较上周的12.39元下跌2.26%。本周,方盛制药3月2日盘中最高价报12.45元。本周关注点来自公司公告汇总:依折麦布片等六款产品中选集采接续采购,2024年度相关收入达4.93亿元。公司公告汇总方盛制药关于产品中选集采药品协议期满品种接续采购的公告2026年2月9日,湖南方盛制药股份有限公司参与国家组织集采第1-8批协议期满品种接续采购申报。截至目前,该药品项目累计投入约898万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800001112.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","603998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617851063","title":"方盛制药(603998)披露比索洛尔氨氯地平片获得《药品注册证书》公告,3月5日股价上涨0.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617851063","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617851063?lang=zh_cn&edition=full","pubTime":"2026-03-05 17:29","pubTimestamp":1772702977,"startTime":"0","endTime":"0","summary":"截至2026年3月5日收盘,方盛制药报收于11.79元,较前一交易日上涨0.6%,最新总市值为51.77亿元。方盛制药于近日披露《关于比索洛尔氨氯地平片获得〈药品注册证书〉的公告》。公告显示,2026年3月3日,公司全资子公司广东方盛健盟药业有限公司收到国家药监局核准签发的《药品注册证书》,比索洛尔氨氯地平片获准生产。国内已有24家企业取得该药品注册证书,2025年前三季度销售额突破1亿元,同比增长248.78%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500028332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["MXPmain","603998","BK0060","EWW","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616580325","title":"方盛制药(603998.SH):比索洛尔氨氯地平片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2616580325","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616580325?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:24","pubTimestamp":1772612640,"startTime":"0","endTime":"0","summary":"智通财经APP讯,方盛制药(603998.SH)发布公告,2026年3月3日,公司全资子公司广东方盛健盟药业有限公司(简称“健盟药业”)收到国家药品监督管理局核准签发的《药品注册证书》,公司研发的比索洛尔氨氯地平片已获得药品批准文号,并可进行生产。该药品适应症:作为高血压治疗的替代疗法,用于目前同时服用与复方制剂剂量相同的单药且血压控制良好的患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409919.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWW","BK0060","603998","MXPmain","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616382110","title":"方盛制药(603998.SH)部分产品中选集采药品协议期满品种接续采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2616382110","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616382110?lang=zh_cn&edition=full","pubTime":"2026-03-02 17:14","pubTimestamp":1772442842,"startTime":"0","endTime":"0","summary":"本次接续采购由全国各省和新疆生产建设兵团组成采购联盟,委托江苏省、河南省和广东省牵头,对原国家组织集采1-8批协议期满的品种,开展全国统一接续采购工作。采购周期中,医疗机构将优先使用本次接续采购中选药品,并确保完成约定采购量。若公司后续签订采购合同并实施后,将有利于进一步扩大相关产品的销售规模,提高市场占有率,促进公司制剂业务的进一步发展,提升公司的品牌影响力,对公司未来经营具有积极影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409004.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603998","BK0060","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616586845","title":"每周股票复盘:方盛制药(603998)张庆华解除质押962.52万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616586845","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616586845?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:40","pubTimestamp":1772304022,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘,方盛制药报收于12.39元,较上周的12.4元下跌0.08%。本周,方盛制药2月24日盘中最高价报12.64元。本周关注点公司公告汇总:控股股东张庆华解除质押962.52万股,占其直接持股的6.17%。本次解除质押股份暂无再次质押计划。方盛制药关于2025年度利润分配相关事项征求投资者意见的公告湖南方盛制药股份有限公司根据相关规定,为做好2025年度利润分配工作,现向广大投资者征求关于利润分配的意见。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000949.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","603998","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614354810","title":"方盛制药(603998)披露控股股东部分股份解除质押公告,2月25日股价下跌0.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614354810","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614354810?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:44","pubTimestamp":1772030652,"startTime":"0","endTime":"0","summary":"截至2026年2月25日收盘,方盛制药报收于12.54元,较前一交易日下跌0.48%,最新总市值为55.06亿元。近日,方盛制药发布《关于控股股东部分股份解除质押的公告》。公告显示,公司控股股东张庆华先生于2026年2月25日办理完成962.52万股公司股份解除质押手续,占其直接持股的6.17%,占公司总股本的2.19%。本次解押后,张庆华先生直接持有公司股份156,019,500股,占公司总股本的35.53%;其累计质押股份为54,450,000股,占其直接持股的34.90%,占公司总股本的12.40%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500038336.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603998","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613739693","title":"股市必读:方盛制药(603998)2月13日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2613739693","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613739693?lang=zh_cn&edition=full","pubTime":"2026-02-24 01:44","pubTimestamp":1771868650,"startTime":"0","endTime":"0","summary":"截至2026年2月13日收盘,方盛制药报收于12.4元,下跌0.64%,换手率1.56%,成交量6.84万手,成交额8559.04万元。机构调研要点公司依折麦布片、头孢克肟片、头孢丙烯片、厄贝沙坦氢氯噻嗪片、奥美拉唑肠溶片及蒙脱石散拟中选国家组织集采药品协议期满品种接续采购,最终结果以官方通知为准。养血祛风止痛颗粒定位治疗频发性紧张型头痛,计划2026年覆盖超500家公立医疗机构,销售收入超过玄七健骨片首年水平,目前已在部分医院实现准入销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400007256.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","603998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611171901","title":"【机构调研记录】平安基金调研泽璟制药、方盛制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2611171901","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611171901?lang=zh_cn&edition=full","pubTime":"2026-02-16 08:01","pubTimestamp":1771200068,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及2月13日披露的机构调研信息,平安基金近期对2家上市公司进行了调研,相关名单如下:1)泽璟制药 调研纪要:泽璟制药与艾伯维就ZG006达成战略合作,艾伯维获大中华区以外开发与商业化权利,泽璟获1亿美元首付款。重组人凝血酶由远大生命科学推广,销量增长明显,已纳入两项权威指南。研发费用率预计将平稳上升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021600000189.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","603998","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610576449","title":"股市必读:方盛制药(603998)2月11日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2610576449","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610576449?lang=zh_cn&edition=full","pubTime":"2026-02-12 00:50","pubTimestamp":1770828620,"startTime":"0","endTime":"0","summary":"截至2026年2月11日收盘,方盛制药报收于12.38元,下跌0.4%,换手率1.4%,成交量6.14万手,成交额7642.77万元。力争2026年覆盖公立医疗机构超500家,销售收入超过玄七健骨片首年水平。目前2026年经营计划暂未完成,后续将根据进展提交董事会或股东会审议并披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021200001108.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0060","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610280556","title":"方盛制药:公司董事会、管理层高度重视市值维护","url":"https://stock-news.laohu8.com/highlight/detail?id=2610280556","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610280556?lang=zh_cn&edition=full","pubTime":"2026-02-10 20:34","pubTimestamp":1770726840,"startTime":"0","endTime":"0","summary":"登录新浪财经APP 搜索【信披】查看更多考评等级\n证券日报网讯 2月10日,方盛制药在互动平台回答投资者提问时表示,公司董事会、管理层高度重视市值维护,已将市值管理纳入部分高级管理人员绩效考核指标。公司将不断完善信息披露机制、加大与投资者沟通力度,增强投资者对公司的直观认知,传递公司价值;此外,公司严格执行积极、稳定的现金分红政策,回报全体股东。公司坚持专注于主业的长期可持续发展,通过不断加强经营管理等各项工作,推动公司持续稳定发展、不断创造价值,以公司的高质量发展积极回报广大投资者。(文章来源:证券日报)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-10/doc-inhmixiy4390054.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-10/doc-inhmixiy4390054.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","603998","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609321041","title":"方盛制药(603998.SH)控股子公司获得《药品生产许可证》","url":"https://stock-news.laohu8.com/highlight/detail?id=2609321041","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609321041?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:05","pubTimestamp":1770278726,"startTime":"0","endTime":"0","summary":"智通财经APP讯,方盛制药(603998.SH)发布公告,近日,公司控股子公司广东方盛融华药业有限公司(简称“方盛融华”)收到广东省药品监督管理局颁发的《药品生产许可证》,同意方盛融华作为药品上市许可持有人,方盛制药作为受托方,受托产品为瑞卢戈利片。本次获得《药品生产许可证》,有利于公司及子公司整合和分配生产销售资源,提高产能利用率,降低生产成本。本次获得《药品生产许可证》短期内不会对公司业绩产生重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","603998","BK0060"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777516041400,"stockEarnings":[{"period":"1week","weight":0.0588},{"period":"1month","weight":0.0009},{"period":"3month","weight":-0.0711},{"period":"6month","weight":-0.0952},{"period":"1year","weight":0.1677},{"period":"ytd","weight":-0.0106}],"compareEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":0.047},{"period":"3month","weight":-0.0121},{"period":"6month","weight":0.0386},{"period":"1year","weight":0.2498},{"period":"ytd","weight":0.0349}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖南方盛制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"24973人(较上一季度减少10.49%)","perCapita":"17582股","listingDate":"2014-12-05","address":"湖南省长沙市岳麓区高新区麓松路789号","registeredCapital":"43908万元","survey":" 湖南方盛制药股份有限公司的主营业务是药品的研发、生产与销售。公司的主要产品是血塞通分散片、血塞通片、藤黄健骨片、赖氨酸维B12颗粒、头孢克肟片、金英胶囊、蒲地蓝消炎片、小儿荆杏止咳颗粒、依折麦布片、玄七健骨片、强力枇杷膏(蜜炼)、强力枇杷露。近三年(2023-2025年)公司先后获得国家绿色工厂、中成药百强工业、湖南省智能制造标杆车间、湖南省消费品工业“三品”标杆企业、湖南省“高新技术企业税收贡献百强”等多项荣誉称号。","listedPrice":14.85},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"方盛制药(603998)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供方盛制药(603998)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"方盛制药,603998,方盛制药股票,方盛制药股票老虎,方盛制药股票老虎国际,方盛制药行情,方盛制药股票行情,方盛制药股价,方盛制药股市,方盛制药股票价格,方盛制药股票交易,方盛制药股票购买,方盛制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"方盛制药(603998)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供方盛制药(603998)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}